NCT02181218View on ClinicalTrials.gov

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 4, 2015

Primary Completion Date

March 28, 2019

Study Completion Date

June 26, 2020

Conditions
Lymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralHodgkin DiseaseLymphoma, Large B-Cell, Diffuse
Interventions
DRUG

Romidepsin

DRUG

Gemcitabine

DRUG

Oxaliplatin

DRUG

Dexamethasone

DRUG

Pegfilgrastim

Trial Locations (2)

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Washington University School of Medicine

OTHER